Cascadian Therapeutics (CASC)

[cash2go]

patient population

This study is a randomized (2 getting vaccine for every 1 getting placebo), double-blind (both sides will get injections on the same schedule, so it won’t be clear who’s receiving active treatment), placebo-controlled trial of 1300 patients with stage IIIB unresectable locoregional (”dry”, without a malignant pleural effusion) who have demonstrated a response or stable disease after at least two cycles of platinum-based chemo with radiation.

http://onctalk.com/?p=247

"locoregional (”dry”, without a malignant pleural effusion)", patient profile more likely to have chemotherapy cures. Hard to find a median survival with BSC for this subpopulation, anyone?